{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:57:12Z","timestamp":1789541832702,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Determining the optimal timing for initiating guideline-directed medical therapy (GDMT) in survivors of cardiogenic shock remains a clinical challenge. Clinicians must balance the urgency of early intervention to prevent adverse remodeling with the risk of hemodynamic instability. This study tested the hypothesis that initiating GDMT early during the intensive care unit (ICU) stay is associated with improved 6-month clinical outcomes in this high-risk population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In a retrospective, two-center study of 42 survivors of Impella\n                      <jats:sup>\u00ae<\/jats:sup>\n                      -supported cardiogenic shock, patients were stratified by their simple GDMT score at ICU discharge (high-score group: score\u2009\u2265\u20094,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200924 vs. low-score group: score\u2009&lt;\u20094,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918). The primary endpoint was a 6-month composite of all-cause mortality and heart failure readmission.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The high-score group demonstrated significantly superior 6-month event-free survival compared to the low-score group (log-rank\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Additionally, this group achieved higher GDMT scores at hospital discharge (median: 8.0 vs. 2.0,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), with a greater proportion achieving a score\u2009\u2265\u20095 (83.3% vs. 27.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that early initiation of GDMT during ICU stabilization is associated with improved 6-month outcomes in survivors of cardiogenic shock. This hypothesis-generating study provides a rationale for future prospective trials to validate this goal-directed strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-025-05311-5","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T09:28:01Z","timestamp":1763544481000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Early initiation of guideline-directed medical therapy in patients with cardiogenic shock supported with Impella\u00ae: a two-center retrospective study"],"prefix":"10.1186","volume":"25","author":[{"given":"Junichiro","family":"Yokawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Shimojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuma","family":"Amino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Koshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"5311_CR1","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1161\/CIR.0000000000001063","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure. Circulation. 2022;145:e876\u201394. https:\/\/doi.org\/10.1161\/CIR.0000000000001063.","journal-title":"Circulation"},{"issue":"36","key":"5311_CR2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"key":"5311_CR3","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/nejm200105313442201","volume":"344","author":"M Packer","year":"2001","unstructured":"Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651\u20138. https:\/\/doi.org\/10.1056\/nejm200105313442201.","journal-title":"N Engl J Med"},{"key":"5311_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/nejm199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709\u201317. https:\/\/doi.org\/10.1056\/nejm199909023411001.","journal-title":"N Engl J Med"},{"key":"5311_CR5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"key":"5311_CR6","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","volume":"143","author":"M Packer","year":"2021","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Effect of empagliflozin on clinical stability of patients with hfref: the EMPEROR-Reduced trial. Circulation. 2021;143:326\u201339. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051783.","journal-title":"Circulation"},{"key":"5311_CR7","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jacc.2019.01.018","volume":"73","author":"PL Myhre","year":"2019","unstructured":"Myhre PL, Vaduganathan M, Claggett B, Packer M, Desai AS, Rouleau JL, et al. BNP during treatment with sacubitril\/valsartan: PARADIGM-HF trial. J Am Coll Cardiol. 2019;73:1264\u201372. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.018.","journal-title":"J Am Coll Cardiol"},{"key":"5311_CR8","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Maggioni AP, et al. STRONG-HF trial: up-titration of GDMT in acute heart failure. Lancet. 2022;400:1938\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(22)02076-1.","journal-title":"Lancet"},{"key":"5311_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","volume":"396","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedrotty DM, Rizkala AR, et al. Estimating lifetime benefits of GDMT in HFrEF. Lancet. 2020;396:121\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(20)30748-0.","journal-title":"Lancet"},{"key":"5311_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jchf.2021.09.004","volume":"10","author":"J Tromp","year":"2022","unstructured":"Tromp J, Ouwerkerk W, van Veldhuisen DJ, Anker SD, Metra M, Samani NJ, et al. Network meta-analysis of GDMT in HFrEF. JACC Heart Fail. 2022;10:117\u201327. https:\/\/doi.org\/10.1016\/j.jchf.2021.09.004.","journal-title":"JACC Heart Fail"},{"key":"5311_CR11","doi-asserted-by":"publisher","first-page":"105573","DOI":"10.1016\/j.phrs.2021.105573","volume":"169","author":"J Bao","year":"2021","unstructured":"Bao J, Kan R, Chen J, Zhai M, Zhang X, Liu J, et al. Combination pharmacotherapies for reverse remodeling in HFrEF. Pharmacol Res. 2021;169:105573. https:\/\/doi.org\/10.1016\/j.phrs.2021.105573.","journal-title":"Pharmacol Res"},{"key":"5311_CR12","doi-asserted-by":"publisher","first-page":"e030975","DOI":"10.1161\/JAHA.123.030975","volume":"13","author":"K Matsushita","year":"2024","unstructured":"Matsushita K, Delmas C, Marchandot B, Kibler M, Ohbe H, Sato N, et al. Optimal heart failure medical therapy and mortality in survivors of cardiogenic shock: insights from the FRENSHOCK registry. J Am Heart Assoc. 2024;13:e030975. https:\/\/doi.org\/10.1161\/JAHA.123.030975.","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"5311_CR13","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1002\/ejhf.2378","volume":"23","author":"PM Seferovi\u0107","year":"2021","unstructured":"Seferovi\u0107 PM, Polovina M, Adlbrecht C, Karavidas A, Lainscak M, Piepoli MF, et al. Navigating between scylla and charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. Eur J Heart Fail. 2021;23(12):1999\u20132007. https:\/\/doi.org\/10.1002\/ejhf.2378.","journal-title":"Eur J Heart Fail"},{"key":"5311_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/ehf2.14863","volume":"11","author":"MG Dimond","year":"2024","unstructured":"Dimond MG, Rosner CM, Lee SB, Li C, Doran JM, Khalid N, et al. Guideline-directed medical therapy implementation during hospitalization for cardiogenic shock. ESC Heart Fail. 2024;11:60\u201370. https:\/\/doi.org\/10.1002\/ehf2.14863.","journal-title":"ESC Heart Fail"},{"key":"5311_CR15","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJMoa2307227","volume":"389","author":"H Thiele","year":"2023","unstructured":"Thiele H, Zeymer U, Akin I, Jobs A, Fuernau G, de Waha-Thiele S, et al. Extracorporeal life support in infarct-related cardiogenic shock. N Engl J Med. 2023;389:1286\u201397. https:\/\/doi.org\/10.1056\/NEJMoa2307227.","journal-title":"N Engl J Med"},{"key":"5311_CR16","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1002\/ehf2.14524","volume":"10","author":"R Matsukawa","year":"2023","unstructured":"Matsukawa R, Okahara A, Tokutome M, Ouchi K, Nishihara T, Nomura A, et al. A scoring evaluation for the practical introduction of guideline-directed medical therapy in heart failure patients. ESC Heart Fail. 2023;10:3352\u201363. https:\/\/doi.org\/10.1002\/ehf2.14524.","journal-title":"ESC Heart Fail"},{"key":"5311_CR17","doi-asserted-by":"publisher","first-page":"e011164","DOI":"10.1161\/CIRCHEARTFAILURE.123.011164","volume":"17","author":"MS Khan","year":"2024","unstructured":"Khan MS, Chan PS, Sherrod CF, Ahmed MI, Butler J, DeVore AD, et al. A generalizable approach to quantifying guideline-directed medical therapy. Circ Heart Fail. 2024;17:e011164. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.123.011164.","journal-title":"Circ Heart Fail"},{"key":"5311_CR18","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.3390\/jcm13102775","volume":"13","author":"T Asano","year":"2024","unstructured":"Asano T, Maeno Y, Nakano M, Kinoshita D, Tanaka Y, Hasegawa T, et al. Validation of a new scoring method to assess the efficacy of rapid initiation and Titration of combination pharmacotherapy for patients hospitalized with acute decompensated heart failure with reduced and mildly reduced ejection fraction. J Clin Med. 2024;13:2775. https:\/\/doi.org\/10.3390\/jcm13102775.","journal-title":"J Clin Med"},{"key":"5311_CR19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2024.10510","volume":"332","author":"CAM Tavares","year":"2024","unstructured":"Tavares CAM, Azevedo LCP, Rea-Neto \u00c1, Damiani LP, Costa ELV, Alexandre P, et al. Dapagliflozin for critically ill patients with acute organ dysfunction: the DEFENDER randomized clinical trial. JAMA. 2024;332:401\u201311. https:\/\/doi.org\/10.1001\/jama.2024.10510.","journal-title":"JAMA"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05311-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-05311-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05311-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T09:28:01Z","timestamp":1763544481000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-05311-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5311"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-05311-5","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective, multicenter, observational study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol received approval from the Institutional Review Board of Kanazawa University Hospital (approval number: 2024-091). Owing to the retrospective design, the requirement for written informed consent was waived by the Institutional Review Board of Kanazawa University Hospital. Instead, study details were posted on the hospital website to allow patients the opportunity to opt out.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"818"}}